At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 139 enrolled
Drug / intervention
EN3267drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients
In Brief
A Phase 3 clinical trial evaluating EN3267 for Pain and Cancer. Completed, enrolled 139 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.
Study Details
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedDec 2005
Primary CompletionDec 2008
Study CompletionJan 2009
TodayJul 2026
First PostedDec 9, 2005
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.6 years ago
Interventions
EN3267drug
EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses